How and when should we monitor chimerism after allogeneic stem cell transplantation?
about
Post-hematopoietic stem cell transplantion immune-mediated cytopenias.Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience.Evaluation of blood, buccal swabs, and hair follicles for DNA profiling technique using STR markersLong-Term Stable Mixed Chimerism after Hematopoietic Stem Cell Transplantation in Patients with Non-Malignant Disease, Shall We Be Tolerant?Chimerism and outcomes after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning.ABO chimerism determined by real-time polymerase chain reaction analysis after ABO-incompatible haematopoietic stem cell transplantation.Donor cell leukemia: a critical review.Pharmacokinetics, Pharmacodynamics and Pharmacogenomics of Immunosuppressants in Allogeneic Haematopoietic Cell Transplantation: Part ITreatment options for the management of acute leukaemia relapsing following an allogeneic transplant.Mixed chimerism in SCT: conflict or peaceful coexistence?Digital PCR Panel for Sensitive Hematopoietic Chimerism Quantification after Allogeneic Stem Cell Transplantation.Recent advances in quantitative chimerism analysis.The Relationship between STR-PCR Chimerism Analysis and Chronic GvHD Following Hematopoietic Stem Cell Transplantation.The applications of bone marrow-derived stem cells to induce tolerance and chimerism in organ transplantation.Lineage-specific chimerism analysis in nucleated cells, T cells and natural killer cells after myeloablative allogeneic hematopoietic stem cell transplantation.Early phase mixed chimerism in bone marrow does not affect long-term outcomes of myeloablative single-unit cord blood transplantation for adult patients with hematological malignancies.Chimerism analysis in clinical practice and its relevance for the detection of graft rejection and malignant relapse in pediatric hematopoietic stem cell transplant patients.Expansion of recipient-derived antiviral T cells may influence donor chimerism after allogeneic stem cell transplantation.Analysis of donor-type chimerism in lineage-specific cell populations after allogeneic myeloablative and non-myeloablative stem cell transplantation.Increasing hematopoietic microchimerism is a reliable indicator of incipient AML relapse.Acute GVHD is a strong predictor of full donor CD3+ T cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation.Major ABO-incompatible hematopoietic stem cell transplantation: study of post-transplant pure red cell aplasia and endothelial cell chimerism.Early recipient chimerism testing in the T- and NK-cell lineages for risk assessment of graft rejection in pediatric patients undergoing allogeneic stem cell transplantation.Developing an algorithm of informative markers for evaluation of chimerism after allogeneic bone marrow transplantation.Analysis of post-transplant chimerism by using a single amplification reaction of 38 Indel polymorphic loci.Evaluation of chimerism by quantitative PCR analysis of DNA polymorphism after allogeneic hematopoietic stem cell transplantation in a pediatric population with malignancies.Quantitative monitoring of multi-donor chimerism: a systematic, validated framework for routine analysis.Clonal cytogenetic abnormalities after tyrosine kinase inhibitor therapy in Ph+ ALL resolution after decitabine therapy.
P2860
Q33390807-5E860E58-2F08-4562-8C12-29000AD3E419Q34549230-B4C1A414-5F35-40B2-8DE2-C8C08C9E89B0Q35847852-28F07F99-5660-4FAA-A97A-5F5B07EC933DQ36010605-345D01F0-B267-4A4C-8C61-6A332BD3D416Q36548358-E67695F8-2B4E-41FD-A070-E7C830404C0CQ36569021-682F6016-BB22-498E-9E71-D98632C3EF7EQ36746425-0419288B-8B81-4F74-94E3-8197D382508AQ36777599-BFBC34E5-C41E-4B11-8A20-6B1D58BDC90AQ36977560-4A3E7F74-63F9-4431-ABF9-1EEF6AE3B004Q37228383-89CD024B-67F4-4ADB-90DB-1D9601741D6BQ37286538-E706BAF6-4500-47FE-8F2A-A479E72A6425Q37628681-CE2ADDF6-0C68-46D8-B1B4-9811030810C2Q37682117-6516F643-8E38-404A-8D0C-A6ECCF920266Q38228330-90F44062-3182-400E-A0F2-945CD12BC805Q39764454-D2385DF4-0EE8-4BE6-8622-BAE10B7075C0Q39813829-7110E04E-6E4F-4CCF-A138-6F7CBFC46C66Q40625577-B166C5E0-0943-48A5-BB5A-A24FCF6DBF60Q42258301-72595457-A3EB-449E-A12A-3952FD9B0537Q45230503-73B70117-1893-44BF-A021-B00CE1F78877Q45862572-0BBE57CB-F6A6-45E8-A931-B486CFD202A9Q47236287-79AF7DAA-D299-40B0-9CFE-5DD659736EBAQ50736799-9DA6D0AB-D0BB-4392-A8C6-7A3BAA65EE9AQ50790158-42E2EB68-F229-4522-98AD-0DC5EABDF40DQ51947741-E760066C-7641-4BDD-B4E1-60924F91ACB2Q54195238-14F0CAB1-F141-4E9F-9301-2A37A8DC823CQ54397268-A5F4F6FE-3E27-404B-838A-403AFDA35511Q54478751-B420EA49-E425-4032-AB23-280375B8A705Q54561399-F3D28880-4869-4D98-B92A-174F9D5C2A11
P2860
How and when should we monitor chimerism after allogeneic stem cell transplantation?
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
How and when should we monitor chimerism after allogeneic stem cell transplantation?
@ast
How and when should we monitor chimerism after allogeneic stem cell transplantation?
@en
type
label
How and when should we monitor chimerism after allogeneic stem cell transplantation?
@ast
How and when should we monitor chimerism after allogeneic stem cell transplantation?
@en
prefLabel
How and when should we monitor chimerism after allogeneic stem cell transplantation?
@ast
How and when should we monitor chimerism after allogeneic stem cell transplantation?
@en
P2093
P2860
P356
P1476
How and when should we monitor chimerism after allogeneic stem cell transplantation?
@en
P2093
D Niethammer
H Kreyenberg
T Klingebiel
P2860
P2888
P304
P356
10.1038/SJ.BMT.1704715
P407
P577
2005-01-01T00:00:00Z